What Approach can Primary Care Physicians Adopt to Manage their Patient who is Upset as a Result of Adverse Effect from their Treatment?

The article explores the various approaches a doctor can use in managing and upset patient. These approaches include BATHE (Background-Affect-Troubles-Handling-Empathy), LEARN (Listen-Explain-Acknowledge-Recommend and Negotiate) and LEAP (Listen-Empathise-Agree-Partnership). We include a case study of a 16 year old patient who presented with a sore throat. She subsequently developed a rash after starting Amoxicillin, which was later changed to Augmentin. The doctor utilised the BATHE approach in managing the patient’s unhappiness.

Selective agent and A. tumefaciens overgrowth-control antibiotics in Eucalyptus camaldulensis Cotiledonary culture

The objectives of the present work were to establish the minimal lethal dose of the selective agent to determine the type and concentration of appropriate antibiotics for the elimination of Agrobacterium tumefaciens inoculated explants, without interfering with the regenerative potential of the E. camaldulensis cotyledonary explants. Non-transformed explants were cultivated in medium supplemented with kanamycin. The results showed that the antibiotic was suitable for the selection of transformed cells in the concentration of 9 mg L-1 as it inhibited the growth of non-transformed cells. Cotyledons infected with A. tumefaciens were cultivated in MS N/2 medium supplemented with BAP, ANA, Km and cefotaxime or AugmentinÒ . The highest average of regenerated shoots by explant (5,4) was observed in the presence of 300 mg L-1 of AugmentinÒ /15 days, followed by 150 mg L-1/15 days and 100 mg L-1/30 days.

O presente trabalho teve como objetivos determinar o tipo e a concentração de antibióticos adequados para a eliminação de Agrobacterium tumefaciens de explantes inoculados e estabelecer a dose letal mínima do agente seletivo canamicina (Km), sem interferir com o potencial regenerativo do explante cotiledonar de E. camaldulensis. Para a avaliação da eficiência dos antibióticos, cotilédones infectados com A. tumefaciens foram cultivados em meio MS N/2 com BAP, ANA, canamicina e cefotaxima ou AugmentinaÒ . Foi observada a maior média de brotos regenerados por explante (5,4) na presença de 300 mg.L-1 de AugmentinaÒ /15 dias, seguido por 150 mg.L-1/30 dias, e 100 mg.L-1/30 dias. Explantes cotiledonares não transformados foram cultivados em meio de cultura suplementado com antibiótico canamicina onde a concentração adequada para a seleção de células transformadas foi de 9 mg.L-1.

Studies of the anti-bacterial activities of Augmentin on common pathogenic bacteria in children / 第三军医大学学报

Objective To understand the drug tolerance of Augmentin for Escherichia coli , Klebsiella pneumoniae spp and other pathogens Methods The MIC, MBC and bactericidal curves of Augmentin of 135 clinically isolated pathogenic bacteria were assayed The anti bacterial activity and clinical effect between Augmentin, Cefurxine, Ceftriaxone, Amoxicillin and Cefazolin were compared by MIC 50 , MIC 90 , MBC 50 , MBC 90 and modal number MIC,MBC Results Augmentin was better than the same kind of antibiotic without ? lactamase inhibitor It had a good effect for anti bacteria activity of extend spectrum ? lactamase (ESBLs) Escherichia coli and Klebsiella pneumoniae spp Conclusion Augmentin can be used for infection of ESBLs and other common pathogenic bacteria, since it has a good anti bacterial activity for most clinicaly isolated pathogenic bacteria and productive enzyme bacteria

SYNER6ISM OF TWO DRUGS COMBIANTION OF AUGMENTIN AND FOUR ANTIBIOTICS / 中国药理学通报

In vitro synergistic activity of augmentin and amikacini sulfas, gentamicini sulfatis, cefazolinum natricum cloxacillinum natricum against 162 strains organism isolated from the clinical laboratories in Beijing were investigated. The results showed: At 8mg/L clavula-nic acid and 16mg/L amoxicillin of augmentin. Combined with 4 antibiotics against staphylococcus aureus, klebsiella pneumoniae shi-gella dysenteriae were showed 100% synergistic activity. The combination of augmentin and gentamicini sulfatis and amikacini sulfas against proteus vulgaris showed: Synergistic in 80% and 85%; against Escherichia coli synergistic in 93.33%; against Enterobacter cloacae synergistic in 17.86% and 42.86%, the combination of augmentin and cefazolinum natricum against Escherichia coli and proteus synergistic in all 100% and 85%.The combination of augmentin and cefazoliinum natricum against enterobacter cloacae in 100% antagonism.

Clinical Study of Augmentin in G-U Tract Infection / 대한비뇨기과학회지

Augmentin is a formulation of amoxycillin trihydrate and potassium clavulanate, a fused beta-lactam molecule produced by the fermentation of straptomyces clavuligerus. Most clinically important resistance is due to the production by bacteria of antibiotic destroying enzymes. In the case of penicillins and cephalospolins these enzymes are termed beta-lactamse as they destroy the beta-lactam ring of these antibiotics completely inactivating them. The presence of clavulanic acid extends the spectrum of amoxycillin to include beta-lactamse producing strains of common pathogens such as Staphylococcus, H influenza, E. coli, Neisseria spp, Proteus spp, Salmonella and Shigella. On clinical study of Augmenting in the field of Genitourinary tract infection cases. We selected randomly 30 patients, 20 males and 10 females, age from 21 to 71, in the period from October, 1985 to February, 1986. Among the total 30 patients, 15 were uncomplicated urinary tract infection and 15 were complicated urinary tract infection. Of the 15 patients with uncomplicated urinary tract infection, 14 patients had not bacteriuria after therapy and 1 patient was not changed. The clinical efficacy rate was 93.4%. Of the 4 patients with persistent infection, 2 patients had resistant P. aeruginosa, and 2 patients had S marcescens persistantly. The clinical efficacy rate was 73.4%. In 2 cases, mild diarrhea was developed, but medication was not stopped. The liver and renal function were normal range before and after treatment.